Clinical trials: IPF
Healthy Volunteers, IPF
A Phase Ia Clinical Trial of HW241045
This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.
- Trial name
- NCT07448194
- Testing
- HW241045
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Idiopathic Pulmonary Fibrosis(IPF)
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT07121413
- Testing
- SV001
- Where
- 12 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Synvida Biotechnology Co.,Ltd.
Idiopathic Pulmonary Fibrosis, IPF
Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis
This is a randomized, placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension phase to evaluate the efficacy, safety, and tolerability of MN-001 in patients diagnosed with moderate to severe…
- Trial name
- NCT02503657
- Testing
- MN-001
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediciNova
Idiopathic Pulmonary Fibrosis (IPF)
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy
This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the…
- Trial name
- NCT07359963
- Testing
- REGEND007 Cell Therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
IPF and PPF
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。
- Trial name
- NCT07192939
- Testing
- HRS-9813 capsules, HRS-9813 capsule mimetic
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis (IPF)
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12…
- Trial name
- NCT05938920
- Testing
- INS018_055
- Where
- 22 sites in China
- Volunteers
- 71 people
- Sponsor
- InSilico Medicine Hong Kong Limited
IPF
A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
This is a phase 1b randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study of PMG1015 in idiopathic pulmonary fibrosis (IPF) subjects.
- Trial name
- NCT05895565
- Testing
- PMG1015
- Where
- 7 sites in China
- Volunteers
- 29 people
- Sponsor
- Pulmongene Ltd.
IPF, Idiopathic Pulmonary Fibrosis
SB17170 Phase 2 Trial in IPF Patients
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by…
- Conditions
- IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT06747923
- Testing
- SB17170
- Where
- 5 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- SPARK Biopharma
Idiopathic Pulmonary Fibrosis (IPF)
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
The purpose of this revised Phase IIa study is to demonstrate safety of INS018_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT05975983
- Testing
- INS018_055
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Idiopathic Pulmonary Fibrosis, IPF
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo.
- Trial name
- NCT06331624
- Testing
- Tazarotene (GRI-0621)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- GRI Bio Operations, Inc.
IPF
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects
The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and…
- Trial name
- NCT06310746
- Testing
- GARP/TGF-β1 monoclonal antibody
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Idiopathic Pulmonary Fibrosis (IPF)
Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to people with idiopathic pulmonary fibrosis (IPF) . They can only take part if they have completed treatment in a previous study with a medicine called HSK44459.
- Trial name
- IPF (NCT07019090)
- Testing
- HSK44459
- Volunteers
- 120 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Idiopathic Pulmonary Fibrosis, Cough
Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
Orally administered ME-015 (Suplatast Tosilate) has been available on the market as a prescription drug for allergy-related conditions in Japan since 1995 with a good safety and tolerability profile.
- Conditions
- Idiopathic Pulmonary Fibrosis, Cough, IPF, Fibrotic Lung Disease
- Trial name
- COSMIC-IPF (NCT05983471)
- Testing
- ME-015 (Suplatast Tosilate)
- Where
- 6 sites in India
- Volunteers
- 40 people
- Sponsor
- Melius Pharma AB
Asthma, Chronic Obstructive Pulmonary Disease
A Study of Patients With Chronic Disease
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF
- Trial name
- NCT04263727
- Where
- 5 sites in United States
- Volunteers
- 579 people
- Sponsor
- Target PharmaSolutions, Inc.
Idiopathic Pulmonary Fibrosis (IPF)
Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
This study was divided into two parts. The first part was a dose escalation study: a open label dose escalation design was used to evaluate the safety, tolerance and pharmacokinetic characteristics of ZSP1603 in IPF patients.
- Trial name
- NCT05119972
- Testing
- ZSP1603
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
IPF, Fibrosis
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.
- Trial name
- NCT05570058
- Testing
- RXC007
- Where
- 31 sites in Austria, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Redx Pharma Ltd
Idiopathic Pulmonary Fibrosis (IPF)
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
- Trial name
- NCT03832946
- Testing
- GB0139
- Where
- 128 sites in United States, Australia and 13 more
- Volunteers
- 172 people
- Sponsor
- Galecto Biotech AB
IPF
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of HNC1058 given to healthy subjects, compared to placebo.
- Trial name
- NCT05803850
- Testing
- HNC1058 Capsules
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participants and participants with…
- Trial name
- NCT04069143
- Testing
- 18F-BMS-986327
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb